A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Urol Oncol
Main Authors: Khaki, Ali Raza, Li, Ang, Diamantopoulos, Leonidas N., Miller, Natalie J., Carril-Ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Koshkin, Vadim, Park, Joseph, Alva, Ajjai, Bilen, Mehmet A., Stewart, Tyler, Santos, Victor, Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael, Nelson, Ariel, Hoimes, Christopher J., Shreck, Evan, Gartrell, Benjamin A., Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Lythgoe, Mark P., Pinato, David J., Murgic, Jure, Fröbe, Ana, Joshi, Monika, Isaacsson Velho, Pedro, Hahn, Noah, Alonso Buznego, Lucia, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Galsky, Matthew D., Sonpavde, Guru, Yu, Evan Y., Shankaran, Veena, Lyman, Gary H., Grivas, Petros
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8169524/
https://ncbi.nlm.nih.gov/pubmed/33423945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euo.2020.12.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados